Evaluation of Statin Prescribing Guidelines, Practices, Safety, Efficacy, and Pharmacoeconomic Study of Chronic Statin Therapy

Asian Pacific Journal of Health Sciences

View Publication Info
 
 
Field Value
 
Title Evaluation of Statin Prescribing Guidelines, Practices, Safety, Efficacy, and Pharmacoeconomic Study of Chronic Statin Therapy
 
Creator Anupama Koneru
Ayesha Naaz
Madihah
Aliya Begum
Lanka Krishna
 
Subject Adverse drug reaction, Atorvastatin, Cost-effectiveness, Hyperlipidemia, Rosuvastatin
 
Description Hyperlipidemia is a medical health condition, defined as increased total cholesterol, low-density lipoprotein cholesterol or triglycerides and low high-density lipoprotein cholesterol or a combination of such abnormalities. Statins are the most commonly used drugs in the present scenario in cardiovascular diseases for dyslipidemia condition. However, recent studies have shown a wide range of interventions regarding its use in patients receiving statin therapy. This study aims to evaluate various parameters that contribute in the choice of statin therapy which includes the prescribing habits of statins in accordance with the guidelines, safety, efficacy; prevalence of adverse drug reaction associated with statins and cost effectiveness analysis of statin tablets of different brands which are varying in their price. A hospital-based prospective study was conducted in Cardiology Department of Aster Prime Hospital, Hyderabad. A total of 170 cases were collected in case collection forms. Data in relation to age, gender, investigations done to obtain final diagnosis, and type of statin therapy opted based on the diagnosis made were collected. The results of the study are validated statistically using SPSS software which incorporates mean, standard deviation method, t test, and Chi-square test. Results obtained illustrate that Rosuvastatin was associated with less adverse effects and is considered to be more cost saving, safe, and efficacious when compared with Atorvastatin. It is crucial to find an effective and an equally safe treatment of statins to reduce the further risk of comorbidities associated with hyperlipidemia.
 
Publisher IJPMR Publishing Press
 
Date 2022-01-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
 
Format application/pdf
 
Identifier https://www.apjhs.com/index.php/apjhs/article/view/1691
 
Source Asian Pacific Journal of Health Sciences; Vol. 9 No. 1 (2022): Vol 9 | Issue 1 | January - March 2022; 1-6
2349-0659
2350-0964
 
Language eng
 
Relation https://www.apjhs.com/index.php/apjhs/article/view/1691/1215
 
Rights Copyright (c) 2021 Anupama Koneru, Ayesha Naaz, Madihah, Aliya Begum, Lanka Krishna
https://creativecommons.org/licenses/by/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library